

Applicants: Andrzej Lipkowski et al.
Serial No.: 10/524,343(a §371 of PCT PCT/PL2003/000077)
Filed : January 30, 2006
Page : 3 of 17

Listing of Claims

1. (Canceled)

2. (Currently amended) A compound represented by the formula:

(Tyr-D-Ser-Gly-Phe-NH-)₂

(Tyr-D-Met-Gly-Phe-NH-)₂

(Tyr-D-Leu-Gly-Phe-NH-)₂

(Tyr-D-Gln-Gly-Phe-NH-)₂

(Tyr-D-Ala-Gly-Trp-NH-)₂

(Tyr-D-Ser-Gly-Trp-NH-)₂


(Tyr-D-Thr-Gly-Trp-NH-)₂

(Tyr-D-Met-Gly-Trp-NH-)₂

(Tyr-D-Leu-Gly-Trp-NH-)₂

(Tyr-D-Gln-Gly-Trp-NH-)₂ or

(Tyr-D-Asn-Gly-Phe-NH-)₂ , wherein the compound has the structure



wherein R₁ is a D-alanine, D-serine, D-threonine, D-methionine, D-leucine, D-asparagine or D-glutamine side_

Applicants: Andrzej Lipkowski et al.
Serial No.: 10/524,343(a §371 of PCT PCT/PL2003/000077)
Filed : January 30, 2006
Page : 4 of 17

chain and ~~is a~~ R₂ is a phenylalanine or tryptophan side-chain.

3. (Previously Presented) An analgesic medication containing the compound of claim 2 and a pharmacologically acceptable carrier.
4. (Canceled)
5. (Previously presented) The analgesic medication according to claim 3, further comprising a compound selected from a group consisting of compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, and compounds blocking cholecystokinin receptors.
6. (Previously presented) The analgesic medication according to claim 3, in the form of an aqueous physiological saline solution.
7. (Previously presented) The analgesic medication according to claim 3, characterised in that it is designed for direct application to the site of the desired analgesic activity.
8. (Previously presented) The analgesic medication according to claim 7, characterised in that it is designed for direct

Applicants: Andrzej Lipkowski et al.
Serial No.: 10/524,343(a §371 of PCT/PL2003/000077)
Filed : January 30, 2006
Page : 5 of 17

application to an appropriate site of the central nervous system.

9. (Previously presented) The analgesic medication according to claim 8, further comprising biphalline.
10. (Canceled)
11. (Withdrawn) A method of alleviating pain in a subject, comprising administering to the subject at the site of the pain a compound according to claim 2.
12. (Withdrawn) The method according to claim 11, wherein the compound is administered directly to the appropriate site of the central nervous system.
13. (Withdrawn) The method according to claim 11, further comprising administering biphalline.
14. (Withdrawn) The method according to claim 11, further comprising administering a compound selected from the group consisting of compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, and compounds blocking cholecystokinin receptors.

Applicants: Andrzej Lipkowski et al.
Serial No.: 10/524,343(a §371 of PCT/PL2003/000077)
Filed : January 30, 2006
Page : 6 of 17

15. (Withdrawn) The method according to claim 11, wherein the compound is administered constantly or periodically.
16. (Withdrawn) The method according to claim 11, wherein the compound is in the form of a solution and it is administered by local infusion.
17. (New) The compound of claim 1, having the formula (Tyr-D-Met-Gly-Phe-NH-)₂.
18. (New) The compound of claim 1, having the formula (Tyr-D-Gln-Gly-Phe-NH-)₂.
19. (New) The compound of claim 1, having the formula (Tyr-D-Leu-Gly-Trp-NH-)₂.
20. (New) The compound of claim 1, having the formula (Tyr-D-Ser-Gly-Phe-NH-)₂.
21. (New) The compound of claim 1, having the formula (Tyr-D-Leu-Gly-Phe-NH-)₂.
22. (New) The compound of claim 1, having the formula (Tyr-D-Ser-Gly-Trp-NH-)₂.

Applicants: Andrzej Lipkowski et al.
Serial No.: 10/524,343(a §371 of PCT/PL2003/000077)
Filed : January 30, 2006
Page : 7 of 17

23. (New) The compound of claim 1, having the formula (Tyr-D-Thr-Gly-Trp-NH-)₂.